Redox Signs Licensing Agreement With OPKO Health, Inc.
On June 12, 2008, OPKO and Redox entered into an agreement whereby OPKO acquired the rights for all ophthalmic uses of Doxovir.
see OPKO Press Release

Redox Pharmaceutical Corporation has been granted approval from Health Canada to perform clinical studies on Herpes Labialis (cold sores).  Phase IB Clinical Trials (initial proof of safety and efficacy) have been successfully completed. A Phase II Clinical Trial on Herpes Labialis has been approved and has now been initiated.

Originally created at the Technion-Israel Institute of Technology, Doxovir™ has been developed by Redox for a variety of medical applications in research in its own laboratory and in collaboration with scientists at

• Baylor College of Medicine
• Beckman Institute at California Institute of Technology
• Columbia University
• Cornell University Weill College of Medicine
• Hadassah Medical School, Jerusalem
• Harvard University
• Mount Sinai School of Medicine
• Penn State University College of Medicine
• Public Health Research Institute of New York
• Rappaport School of Medicine at Technion
• Rush Presbyterian Medical Center in Chicago
• SUNY Stony Brook
• Technion-Israel Institute of Technology
• Tel Aviv University
• University of Alabama
• University of Cincinnati
• University of Rochester Medical School
• University of Utah School of Medicine
• Wayne State University